Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use?

Future Cardiol. 2018 May;14(3s):47-53. doi: 10.2217/fca-2018-0026.

Abstract

Aim: To analyze the evolution of clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban.

Methods: Retrospective study in which patients treated with rivaroxaban were divided into two groups according to the data in which the initial prescription was performed (November 2012-December 2013 and January 2014-January 2017).

Results: 211 patients (mean age 76.7 ± 9.2 years; CHA2DS2-VASc 3.8 ± 1.5; HAS-BLED 2.0 ± 0.8.) were included. Age and bleeding risk were higher in those subjects in which the prescription started earlier. Rates of stroke/TIA, major bleeding and intracranial hemorrhage were 2.3/4.2/0.6 events/100 patient-years, respectively.

Conclusion: Although, the initial prescription of rivaroxaban was mainly performed in very elderly patients and/or with a higher bleeding risk, this has been extended to the overall nonvalvular atrial fibrillation population.

Keywords: ROCKET-AF; atrial fibrillation; clinical practice; clinical profile; rivaroxaban.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy*
  • Factor Xa Inhibitors / therapeutic use*
  • Female
  • Hemorrhage / epidemiology*
  • Humans
  • Male
  • Patient Selection
  • Practice Patterns, Physicians'
  • Retrospective Studies
  • Rivaroxaban / therapeutic use*
  • Stroke / etiology
  • Stroke / prevention & control*
  • Treatment Outcome

Substances

  • Factor Xa Inhibitors
  • Rivaroxaban